Key result
A verapamil SR strategy improved depressive symptoms by 1.45 points (P<0.001) at 1 year, whereas an atenolol strategy yielded a nonsignificant 0.27-point improvement in hypertensive CAD patients.
Why the study?
Does a verapamil SR strategy improve depressive symptoms compared to an atenolol strategy in hypertensive patients with coronary artery disease?
RCT (n=2,317)
randomized
Yes
Does a verapamil SR strategy improve depressive symptoms compared to an atenolol strategy in hypertensive patients with coronary artery disease?
Absolute Event Rate: 1.45% vs 0.27%
p-value: p=<0.001
A verapamil SR-based antihypertensive strategy is associated with improved depressive symptoms compared to an atenolol-based strategy in patients with hypertension and coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Favors verapamil SR over atenolol for depressive symptoms in hypertensive CAD; extends evidence on antihypertensive choice and mood.
Ried et al. (2005) conducted an RCT in Hypertension with coronary artery disease (n=2,317). Verapamil SR strategy vs. Atenolol strategy was evaluated on Depressive symptoms measured by the Center for Epidemiologic Studies-Depression (CES-D) scale (p=<0.001). A verapamil SR strategy improved depressive symptoms by 1.45 points (P<0.001) at 1 year, whereas an atenolol strategy yielded a nonsignificant 0.27-point improvement in hypertensive CAD patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: